By Kyle Morris

AstraZeneca PLC said Monday that Tezspire has been recommended for approval in the EU for the treatment of severe asthma.

The pharmaceutical giant said Tezspire has been recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Asthma is a disease that affects around 14 million people living in the European Union.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

July 25, 2022 02:44 ET (06:44 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Astrazeneca.